scholarly journals Survival and prognostic factor analyses in malignant giant cell tumour of bone

2020 ◽  
Author(s):  
Jin Zhang ◽  
Xin Wang ◽  
Feng Lin ◽  
Guijun Xu ◽  
Haixiao Wu ◽  
...  
Keyword(s):  
Giant Cell ◽  
Cox Regression ◽  
Giant Cell Tumour ◽  
Large Population ◽  
Survival Rates ◽  
Population Based ◽  
Cell Tumour ◽  
Rank Test ◽  
Seer Database ◽  
Cox Proportional Hazard Regression

Abstract Background: The characteristics and survival of patients with malignant giant cell tumour of bone (GCTB) have not been investigated thoroughly due to the rarity of the disease. We evaluated these factors in a large cohort in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database. Methods: Data from patients who were diagnosed with malignant GCTB from 1975 to 2016 were extracted from the SEER database. The overall survival (OS) was calculated by Kaplan–Meier analysis, and intergroup differences were tested by the log-rank test. Univariate and multivariate Cox proportional hazard regression analyses were conducted to identify the independent survival factors. Results: A total of 325 patients with malignant GCTB were included. The overall 1-, 5-, and 10-year survival rates were 94.3% (95% CI: 91.7-96.8), 82.3% (95% CI: 77.9-86.6), and 80.1% (95% CI: 75.4-84.7), respectively. A potential non-linear J-shaped dose–response relationship between the age or diagnosis year and survival. Multivariate Cox regression showed poor survival in patients with age from 35 to 60 years (hazard ratio (HR) =9.99, 95% CI: 1.34-74.80, P =0.025), age older than 60 years (HR=62.03, 95% CI: 7.94-484.38, P <0.001), with stage T2 disease (HR=4.85, 95% CI: 1.52-15.47, P =0.008), with stage T3 disease (HR=6.09, 95% CI: 1.03-36.23, P =0.047), and with distant tumours (HR=2.76, 95% CI: 1.14-6.65, P =0.024), and extraskeletal sites (HR=3.33, 95% CI: 1.02-10.85, P =0.046). Conclusions: This large population-based series described the clinical characteristics of malignant GCTB. Patients with age >34 years, stage T2/3 disease, distant disease and extra-skeletal sites had more odds to be with worse survival.

scholarly journals Survival and prognostic factor analyses in malignant giant cell tumour of bone

2020 ◽  
Author(s):  
Jin Zhang ◽  
Xin Wang ◽  
Feng Lin ◽  
Guijun Xu ◽  
Haixiao Wu ◽  
...  
Keyword(s):  
Giant Cell ◽  
Cox Regression ◽  
Giant Cell Tumour ◽  
Large Population ◽  
Survival Rates ◽  
Population Based ◽  
Cell Tumour ◽  
Rank Test ◽  
Seer Database ◽  
Increased Risk

Abstract Background: The characteristics and survival of patients with malignant giant cell tumour of bone (GCTB) have not been investigated thoroughly due to the rarity of the disease. We evaluated these factors in a large cohort in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database.Methods: Data from patients who were diagnosed with malignant GCTB from 1975 to 2016 were extracted from the SEER database. The overall survival (OS) was calculated by Kaplan–Meier analysis, and intergroup differences were tested by the log-rank test. Univariate and multivariate Cox proportional hazard regression analyses were conducted to identify the independent survival factors.Results: A total of 325 patients with malignant GCTB were included. The overall 1-, 5-, and 10-year survival rates were 94.3% (95% CI: 91.7-96.8), 82.3% (95% CI: 77.9-86.6), and 80.1% (95% CI: 75.4-84.7), respectively. A potential non-linear J-shaped dose–response relationship between the age or diagnosis year and survival were found. Multivariate Cox regression showed poor survival in patients with age from 35 to 60 years (hazard ratio (HR) =9.99, 95% CI: 1.34-74.80, P=0.025), age older than 60 years (HR=62.03, 95% CI: 7.94-484.38, P<0.001), with stage T2 disease (HR=4.85, 95% CI: 1.52-15.47, P=0.008), with stage T3 disease (HR=6.09, 95% CI: 1.03-36.23, P=0.047), and with distant tumours (HR=2.76, 95% CI: 1.14-6.65, P=0.024), and extraskeletal sites (HR=3.33, 95% CI: 1.02-10.85, P=0.046).Conclusions: This large population-based series described the clinical characteristics of malignant GCTB. Patients with stage T2/3disease, distant disease and extra-skeletal sites had more odds to be with worse survival. The elder age than 34 years had a gradually increased risk for survival.

scholarly journals Survival and Prognostic Factors Analyses in Malignant Giant Cell Tumor of Bone

2020 ◽  
Author(s):  
Jin Zhang ◽  
Xin Wang ◽  
Feng Lin ◽  
Guijun Xu ◽  
Haixiao Wu ◽  
...  
Keyword(s):  
Giant Cell ◽  
Cox Regression ◽  
Large Population ◽  
Survival Rates ◽  
Population Based ◽  
Rank Test ◽  
Seer Database ◽  
Kaplan Meier ◽  
Increased Risk ◽  
Cox Proportional Hazard Regression

Abstract Background: The characteristics and survival of patients with malignant giant cell tumour of bone (GCTB) have not been investigated thoroughly due to the rarity of the disease. We evaluated these factors in a large cohort in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database.Methods: Data from patients who were diagnosed with malignant GCTB from 1975 to 2016 were extracted from the SEER database. The overall survival was calculated by Kaplan–Meier analysis, and intergroup differences were tested by the log-rank test. Univariate and multivariate Cox proportional hazard regression analyses were conducted to identify the independent survival factors.Results: A total of 325 patients with malignant GCTB were included. The overall 1-, 5-, and 10-year survival rates were 94.3% (95% CI: 91.7-96.8), 82.3% (95% CI: 77.9-86.6), and 80.1% (95% CI: 75.4-84.7), respectively. A potential non-linear J-shaped dose–response relationship between the age or diagnosis year and survival were found. Multivariate Cox regression showed poor survival in patients with age from 35 to 60 years (HR=9.99, 95% CI: 1.34-74.80, P=0.025), age older than 60 years (HR=62.03, 95% CI: 7.94-484.38, P<0.001), with stage T2 disease (HR=4.85, 95% CI: 1.52-15.47, P=0.008), with stage T3 disease (HR=6.09, 95% CI: 1.03-36.23, P=0.047), and with distant tumours (HR=2.76, 95% CI: 1.14-6.65, P=0.024), and extraskeletal sites (HR=3.33, 95% CI: 1.02-10.85, P=0.046).Conclusions: This large population-based series described the clinical characteristics of malignant GCTB. Patients with stage T2/3 disease, distant disease and extra-skeletal sites had more odds to be with worse survival. The elder age than 34 years had a gradually increased risk for survival.

scholarly journals Survival and prognostic factors analyses in malignant giant cell tumor of bone

2020 ◽  
Author(s):  
Jin Zhang ◽  
Xin Wang ◽  
Feng Lin ◽  
Guijun Xu ◽  
Haixiao Wu ◽  
...  
Keyword(s):  
Cox Regression ◽  
Large Population ◽  
Univariate Analysis ◽  
Survival Rates ◽  
Population Based ◽  
Rank Test ◽  
Seer Database ◽  
Kaplan Meier ◽  
Giant Tumor ◽  
Cox Proportional Hazard Regression

Abstract Background: The characteristics and survival in patients with malignant giant tumor cancer of bone (GCTB) have not been investigated thoroughly due to the limited population. We evaluated the issues based on a large cohort in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database. Methods: Patients who were diagnosed with malignant GCTB from 1975 to 2016 were extracted from the SEER database. The overall survival (OS) was calculated by Kaplan–Meier analysis and the inter-group difference was tested by log-rank test. Univariate and multivariate Cox proportional hazard regression were conducted to identify the independent survival factors. Results: A total of 325 patients with malignant GCTB were included. The overall 1-, 5-, and 10-year survival rates were 94.3% (95% CI: 91.7-96.8), 82.3% (95% CI: 77.9-86.6), and 80.1% (95% CI: 75.4-84.7), respectively. In the univariate analysis, age older than 34 years, grade IV, T2/3 stage, M1, distant and surgery of the primary site were independent factors for worse survival. Multivariate Cox regression showed the poor survival in patients with age older than 34 years (hazard ratio (HR) =3.65, 95% CI: 2.04-6.56, P <0.001), T2 stage (HR=4.85, 95% CI: 1.52-15.47, P =0.008), and distant tumor (HR=2.93, 95% CI: 1.24-6.88, P =0.014), and the extra-skeletal sites (HR=8.84, 95% CI: 2.89-27.07, P <0.001), respectively. Conclusions: This large population-based series described the clinical characteristics of the malignant GCTB. Age >34 years, T2, distant stage and extra-skeletal sites were associated with worse survival in the patients with malignant GCTB.

scholarly journals Survival and prognostic factors analyses in malignant giant cell tumor of bone

2019 ◽  
Author(s):  
Jin Zhang ◽  
Xin Wang ◽  
Feng Lin ◽  
Guijun Xu ◽  
Haixiao Wu ◽  
...  
Keyword(s):  
Cox Regression ◽  
Large Population ◽  
Univariate Analysis ◽  
Survival Rates ◽  
Population Based ◽  
Rank Test ◽  
Seer Database ◽  
Survival Factors ◽  
Giant Tumor ◽  
Distant Tumor

Abstract Background The characteristics and survival in patients with malignant giant tumor cancer of bone (GCTB) were not investigated thoroughly due to the limited population. We evaluated the issues based on a large cohort in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database. Methods Patients who were diagnosed with malignant GCTB from 1975 to 2016 were extracted from the SEER database. The overall survival (OS) was calculated by Kaplan–Meier analysis and the inter-group difference was tested by log-rank test. Univariate and multivariate Cox proportional hazard regression were conducted to identify the independent survival factors. Results A total of 325 patients with malignant GCTB were included. The overall 1-, 5-, and 10-year survival rates were 94.3% (95% CI: 91.7-96.8), 82.3% (95% CI: 77.9-86.6), and 80.1% (95% CI: 75.4-84.7), respectively. In the univariate analysis, age older than 34 years, grade IV, T2/3 stage, M1, distant and surgery of the primary site. Multivariate Cox regression showed the poor survival in patients with age older than 34 years (hazard ratio (HR) =3.68, 95% CI: 2.06-6.57, P<0.001), T2 stage (HR=4.96, 95% CI: 1.57-15.63, P=0.006), distant tumor (HR=3.02, 95% CI: 1.32-6.92, P=0.009), and the extra-skeletal sites (HR=8.84, 95% CI: 2.89-27.07, P<0.001), respectively. Conclusions This large population-based series described the clinical characteristics of the malignant GCTB. Age, T2, distant tumor and extra-skeletal sites were determinant survival factors of the patients with malignant GCTB.

scholarly journals Population-Based Study of Giant Cell Tumour of the Bone in Sweden

2014 ◽  
Vol 25 ◽  
pp. iv509
Author(s):  
J. Amelio ◽  
J. Sandberg ◽  
R. Hernandez ◽  
P. Sobocki ◽  
S. Stryker ◽  
...  
Keyword(s):  
Giant Cell ◽  
Giant Cell Tumour ◽  
Population Based ◽  
Cell Tumour ◽  
Population Based Study

scholarly journals A Population-Based Systematic Clinical Analysis With a Single-Center Case Series of Patients With Pulmonary Large Cell Neuroendocrine Carcinoma

2021 ◽  
Vol 12 ◽  
Author(s):  
Xu Sun ◽  
Yijun Wu ◽  
Jing Shen ◽  
Chang Han ◽  
Kai Kang ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Cox Regression ◽  
Case Series ◽  
Large Cell ◽  
Mortality Rates ◽  
Population Based ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Rank Test ◽  
Seer Database ◽  
Incidence And Mortality

Background and ObjectivesThis study aims to conduct an updated systematic analysis of patients with pulmonary large cell neuroendocrine carcinoma (PLCNC) in recent decades, concerning incidence and mortality trends, demographics, treatments, survival and death causes.MethodsPatients who were diagnosed with PLCNC at the Peking Union Medical College Hospital (PUMCH) between 2000 to 2020 were retrospectively analyzed. The population-based Surveillance, Epidemiology, and End Results (SEER) database were also retrieved. Frequencies and average annual age-adjusted rates (AAR) of PLCNC patients were calculated and analyzed by Joint-point regression. Univariate and multivariate Cox regression were used for identifying prognostic factors. Predictive nomograms for overall survival (OS) and cancer-specific survival (CSS) were developed and then validated by calculating C-index values and drawing calibration curves. Survival curves were plotted using the Kaplan-Meier method and compared by log-rank test. Causes of death were also analyzed by time latency.ResultsA total of 56 PLCNC patients of the PUMCH cohort were included. Additionally, the PLCNC patients in the SEER database were also identified from different subsets. The AAR from 2001 to 2017 were 3.21 (95%CI: 3.12-3.30) per million. Its incidence and mortality rates in PLCNC patients increased at first but seemed to decline in recent years. Besides TNM stage and treatments, older age and male gender were independently associated with poorer survival, while marital status only affected CSS other than OS. The nomograms for OS and CSS presented great predictive ability and calibration performance. Surgery gave significantly more survival benefits to PLCNC patients, and chemotherapy might add survival benefits to stage II-IV. However, radiation therapy seemed to only improve stage III patients’ survival.ConclusionsThis study supported some previous studies in terms of incidence, survival, and treatment options. The mortality rates seemed to decline recently, after an earlier increase. Among PLCNC patients, most of the deaths occurred within the first five years, while other non-PLCNC diseases increased after that. Thus, careful management and follow-up of other comorbidities are of equal importance. Our study may partly solve the dilemma caused by PLCNC’s rarity and inspire more insights in future researches.

scholarly journals Proportion and Prognosis of Bone Metastases from Gastric Cancer in SEER database

2019 ◽  
Author(s):  
zepang sun ◽  
Hao Chen ◽  
Zhen Han ◽  
Jiang Yu ◽  
Weicai Huang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Bone Metastases ◽  
Cox Regression ◽  
Cox Model ◽  
Population Based ◽  
Rank Test ◽  
Seer Database ◽  
Entire Cohort ◽  
Kaplan Meier

Abstract Purpose The purpose of this study was to analyze the proportion and prognosis of bone metastases at diagnosis of gastric cancer using population-based data from SEER. Patients and methods Patients with gastric cancer and bone metastases (GCBM) at the time of diagnosis in advanced gastric cancer were identified using the Surveillance, Epidemiology and End Result (SEER) database of the National Cancer Institute. Multivariable logistic and Cox regression were performed to identify predictors of the presence of GCBM at diagnosis and factors associated with all-cause mortality and gastric cancer-specific mortality. Survival curves were obtained according to the Kaplan-Meier method and compared using the log-rank test. Results We identified 975 patients with gastric cancer and bone metastases at the time of diagnosis, representing 5.31% of the entire cohort and 13.35% of the subset with metastatic disease to any distant site. Among entire cohort, multivariable logistic regression identified five factors (lower age, diffused-type, adverse pathology grade, N1 staging and presence of more extraosseous metastases to liver, lung and brain.) as positive predictors of the presence of bone metastases at diagnosis. Median survival among the entire cohort with GCBM was 4.0 months (interquartile range: 1.0-8.0mo). Multivariable Cox model in SEER cohort confirmed two factors (non-cardia stomach and absence of chemotherapy) as negative predictors for overall survival. We also found poor survival in non-surgical patients using Fine and Gray’s competing risk regression model. Conclusion The findings of this study provided population-based estimates of the proportion and prognosis for GCBM at time of diagnosis. These findings provided guidance for screening and treatment of GCBM patients. Chemotherapy may make benefit for overall survival, but the role of surgery remained to be determined by further research.

Fracture Risk in Patients with Myasthenia Gravis: A Population-Based Cohort Study

2021 ◽  
pp. 1-8
Author(s):  
Charles Kassardjian ◽  
Jessica Widdifield ◽  
J. Michael Paterson ◽  
Alexander Kopp ◽  
Chenthila Nagamuthu ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Lower Risk ◽  
Cox Regression ◽  
Large Population ◽  
Population Based ◽  
Osteoporosis Prevention ◽  
Inception Cohort ◽  
Hazard Ratios ◽  
Multiple Covariates ◽  
Region Of Residence

Background: Prednisone is a common treatment for myasthenia gravis (MG), and osteoporosis is a known potential risk of chronic prednisone therapy. Objective: Our aim was to evaluate the risk of serious fractures in a population-based cohort of MG patients. Methods: An inception cohort of patients with MG was identified from administrative health data in Ontario, Canada between April 1, 2002 and December 31, 2015. For each MG patient, we matched 4 general population comparators based on age, sex, and region of residence. Fractures were identified through emergency department and hospitalization data. Crude overall rates and sex-specific rates of fractures were calculated for the MG and comparator groups, as well as rates of specific fractures. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox regression. Results: Among 3,823 incident MG patients (followed for a mean of 5 years), 188 (4.9%) experienced a fracture compared with 741 (4.8%) fractures amongst 15,292 matched comparators. Crude fracture rates were not different between the MG cohort and matched comparators (8.71 vs. 7.98 per 1000 patient years), overall and in men and women separately. After controlling for multiple covariates, MG patients had a significantly lower risk of fracture than comparators (HR 0.74, 95% CI 0.63–0.88). Conclusions: In this large, population-based cohort of incident MG patients, MG patients were at lower risk of a major fracture than comparators. The reasons for this finding are unclear but may highlight the importance osteoporosis prevention.

scholarly journals AB0049 Rheumatoid arthritis and giant cell tumour of the tendon sheath: A case report

2001 ◽  
Author(s):  
S Kiraz ◽  
D Altýnok ◽  
Ý Ertenli ◽  
MA Öztürk ◽  
S Apras ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Case Report ◽  
Giant Cell ◽  
Giant Cell Tumour ◽  
Tendon Sheath ◽  
Cell Tumour
Sign in / Sign up

Export Citation Format

Share Document